Omidenepag Isopropyl Suppliers & Bulk Manufacturers
Available Forms: Eye Drops
Available Strengths: 0.002%
Reference Brands: Eybelis
Category:
Opthalmology
Omidenepag Isopropyl is available in Eye Drops
and strengths such as 0.002%.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Omidenepag Isopropyl is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Omidenepag Isopropyl can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Omidenepag isopropyl ophthalmic solution 0.002% (EYBELIS®) is a selective prostaglandin E2 receptor subtype 2 (EP2) agonist with a unique non-prostaglandin chemical structure. It has been developed for the treatment of glaucoma and ocular hypertension, conditions characterized by elevated intraocular pressure that can lead to progressive optic nerve damage and vision loss if left untreated. The product is the result of a collaborative development effort between Ube Industries and Santen Pharmaceutical.
Unlike conventional prostaglandin analogs, omidenepag isopropyl acts selectively on the EP2 receptor, promoting increased aqueous humor outflow through both trabecular and uveoscleral pathways. This distinct mechanism of action offers effective intraocular pressure reduction while providing a differentiated therapeutic profile. Omidenepag isopropyl is administered as a once-daily ophthalmic solution, supporting patient compliance in long-term glaucoma management.
Based on positive outcomes from phase III clinical trials demonstrating its efficacy and safety, omidenepag isopropyl ophthalmic solution 0.002% received regulatory approval in Japan in September 2018. This approval marked the first global authorization for this novel EP2 receptor agonist in glaucoma and ocular hypertension treatment, representing an important advancement in ophthalmic therapeutic options.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing